Hba1c of 7.4 percent after 11 months of metformin 250 mg tds
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Based on the clinical scenario and textbook evidence, here is a structured clinical assessment:
Clinical Assessment: HbA1c 7.4% on Metformin 250 mg TDS × 11 months
The Core Problem: Subtherapeutic Dosing
The patient is on metformin 250 mg three times daily (750 mg/day total) — this is significantly below the therapeutic dose range. According to Goodman & Gilman's:
"The maximum dose is 2550 mg, but therapeutic benefit starts to plateau at 2000 mg. It is recommended for twice-daily administration at doses of 0.5 to 1.0 g."
The standard therapeutic range is 1000–2550 mg/day, with most benefit seen at 1500–2000 mg/day. At 750 mg/day, this patient has been on roughly one-third of the effective dose for nearly a year.
The HbA1c of 7.4% likely reflects inadequate drug exposure rather than true treatment failure.
What Should Be Done
Step 1: Titrate metformin to an effective dose first
- Increase incrementally to minimize GI side effects
- Target: 500 mg BD → 500 mg TDS → 1000 mg BD (or 850 mg BD), up to 2000 mg/day
- HbA1c can fall by a further 0.5–2.0% with optimised monotherapy — Harrison's states that metformin dose should be "increased until the glycemic target is achieved or the maximum dose is reached"
- A further reduction of ~0.5–1% is realistically achievable on adequate metformin alone, which could bring HbA1c to ~6.5–6.9%
Step 2: Reassess HbA1c in 3 months after reaching therapeutic dose
HbA1c Target Interpretation
| HbA1c | Interpretation |
|---|---|
| <7.0% | Standard target for most T2DM patients (ADA/Harrison's) |
| 7.4% | Above target — needs intervention |
| <6.5% | Tighter target for younger, low hypoglycemia risk, short duration |
| 7.0–7.9% | Acceptable for older/frail patients with comorbidities |
This patient at 7.4% is just above the standard target of 7.0%, and dose optimisation alone may be sufficient to reach goal.
If HbA1c Remains >7% After Maximum Metformin
Harrison's recommends adding a second agent based on patient comorbidities:
- SGLT-2 inhibitor (e.g. empagliflozin, dapagliflozin) — preferred if established ASCVD or CKD or HF
- GLP-1 RA (e.g. semaglutide, liraglutide) — preferred if obesity or ASCVD; additional weight loss benefit
- DPP-4 inhibitor (e.g. sitagliptin) — weight-neutral, well tolerated, no hypoglycemia
- Sulfonylurea — cheap, effective, but hypoglycemia risk
- Insulin — if HbA1c markedly elevated or symptoms of hyperglycemia
Summary
Do not interpret this as metformin failure. The dose of 750 mg/day has never been therapeutic. Escalate metformin to 1500–2000 mg/day, recheck HbA1c at 3 months, and only then consider dual therapy if the target is still not met.
— Harrison's Principles of Internal Medicine 22E | Goodman & Gilman's Pharmacological Basis of Therapeutics
This is a shared conversation. Sign in to Orris to start your own chat.